Anoro ellipta and Intestinal obstruction - a phase IV clinical study of FDA data

Summary:

Intestinal obstruction is reported as a side effect among people who take Anoro ellipta (umeclidinium bromide; vilanterol trifenatate), especially for people who are male, 60+ old, also take Tylenol, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Intestinal obstruction when taking Anoro ellipta. It is created by eHealthMe based on reports of 16,408 people who have side effects when taking Anoro ellipta from the FDA, and is updated regularly.

What is Anoro ellipta?

Anoro ellipta has active ingredients of umeclidinium bromide; vilanterol trifenatate. eHealthMe is studying from 16,515 Anoro ellipta users. Check the latest studies of Anoro ellipta.

What is Intestinal obstruction?

Intestinal obstruction is found to be associated with 1,886 drugs and 2,613 conditions by eHealthMe. Check the latest studies of Intestinal obstruction.

On Jul, 13, 2026

16,408 people reported to have side effects when taking Anoro ellipta.
Among them, 18 people (0.11%) have Intestinal obstruction.

Could Anoro ellipta cause Intestinal obstruction?

Among these 18 people:

What is the gender of people who have Intestinal obstruction when taking Anoro ellipta? *

female: 43.75 %
male: 56.25 %

What is the age of people who have Intestinal obstruction when taking Anoro ellipta? *

What are other drugs people take besides Anoro ellipta? *

What are other side effects people have besides Intestinal obstruction? *

Weakness: 7 people, 38.89%
Chest Pain: 7 people, 38.89%
Pneumonia: 7 people, 38.89%
Cough: 7 people, 38.89%
Malaise (a feeling of general discomfort or uneasiness): 7 people, 38.89%
White Blood Cell Count Decreased: 6 people, 33.33%
Fluid Retention (an abnormal accumulation of fluid in the blood): 6 people, 33.33%
Kidney Infection: 6 people, 33.33%
Headache (pain in head): 6 people, 33.33%
Wheezing (a high-pitched whistling sound made while you breath): 6 people, 33.33%

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 6 people, 33.33%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 3 people, 16.67%
Type 2 Diabetes: 2 people, 11.11%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 5.56%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 5.56%
Idiopathic Pulmonary Fibrosis (chronic lung disease): 1 person, 5.56%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 5.56%
Colon Cancer: 1 person, 5.56%
Asthma: 1 person, 5.56%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Anoro ellipta and have Intestinal obstruction?

- Check whether Intestinal obstruction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Anoro ellipta:

Anoro ellipta (16,515 reports)

Intestinal obstruction treatments and more:

Intestinal obstruction (59,346 reports)

How severe was Intestinal obstruction and when was it recovered:

Intestinal obstruction in Anoro ellipta

Expand to all the drugs that have ingredients of umeclidinium bromide; vilanterol trifenatate:

Intestinal obstruction and drugs with ingredients of umeclidinium bromide; vilanterol trifenatate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Anoro ellipta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Intestinal obstruction:

Intestinal obstruction (1,886 drugs)

Browse all the conditions that are associated with Intestinal obstruction:

Intestinal obstruction (2,613 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on umeclidinium bromide; vilanterol trifenatate (the active ingredients of Anoro ellipta) and Anoro ellipta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.